GENENTECH USA, INC holds $136.1M across 34 federal awards, concentrated at Department of Health and Human Services (HHS). This PIID sits alongside 1 related award under parent 36F79723D0219. The prior award was single-bid — competitive dynamics may favor a challenge. Recompete timing centers on the Sep 29, 2027 PoP end — agencies typically plan 12–18 months ahead.
PROCURENT OF XOFLUZA (BALOXAVIR MARBOXIL) 40MG AND 80MG TABLETS
Current PoP ends Sep 29, 2027 (429 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.
Track recompete timing in SCOUT →GENENTECH USA, INC — $136.1M obligated across 34 awards (firm-wide, all agencies) · lead buyer Department of Health and Human Services (HHS).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Live Demand-Fit + Displacement scoring, alerts on verdict flips, and watchlists. Free — no card required.
See all live recompete landscapes — who else is expiring, and where the openings are.
Open GENENTECH USA, INC’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Register free to start exploring SCOUT →